English to Russian Medical Medical: Pharmaceuticals

The efficacy and safety of ranibizumab was mainly evaluated in 7 clinical studies in AMD and other indications. Various Phase I to IV clinical trials were conducted with Lucentis® in the above mentioned indications. Ranibizumab has proved to be effective in the treatment of these diseases which were thought to be historically resistant to treatments. Ranibizumab provides not only visual stabilization but also vision gain in neovascular AMD, which has never been achieved with previous treatment modalities. Long-term studies have shown that ranibizumab is well tolerated for over 4 years and has been shown to have very few serious ocular and systemic side effects as compared to other therapies.